

References

L-173

1. Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia: summary of NICE guidance. *BMJ*. 2008;337:a1095.
2. Civeira F, International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. *Atherosclerosis*. 2004;173(1):55-68.
3. Youngblood E, Knowles JW. (January 2, 2014). Familial Hypercholesterolemia. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2015.
4. Safer R. Familial hypercholesterolemia: clues to catching it early. *The Journal of Family Practice*. 2015 Aug; 64(8): 464-469.
5. Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. *Circulation*. 2007;116(6):664-8.
6. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. *Lancet*. 2001 Feb 24;357(9256):577-81.
7. Neil HA, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of under diagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. *BMJ*. 2000;321(7254):148.
8. Leren TP. Cascade genetic screening for familial hypercholesterolemia. *Clin Genet*. 2004;66(6):483-7.
9. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. *Am J Epidemiol*. 2004 Sep 1;160(5):407-20.
10. Cardiac Society of Australia and New Zealand (CSANZ). Guidelines for the diagnosis and management of Familial Hypercholesterolaemia. Available at: http://www.csanz.edu.au/wp-content/uploads/2013/12/Familial_Hypercholesterolemia_2013.pdf.
11. van Aalst-Cohen ES, Jansen AC, Tanck MW, et al. Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. *Eur Heart J*. 2006 Sep;27(18):2240-6.
12. Varret M, Abifadel M, Rabès JP, Boileau C. Genetic heterogeneity of autosomal dominant hypercholesterolemia. *Clin Genet*. 2008 Jan;73(1):1-13.
13. Hopkins, PN, Toth PP, Ballantyne CM, Rader DJ. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the national lipid association expert panel on familial hypercholesterolemia. (2011). *Journal of Clinical Lipidology*. 2011;5(3):S9-S17.
14. Leren TP, Finborud TH, Manshaus TE, Ose L, Berge KE. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. *Community Genet*. 2008;11(1):26-35.

15. *National Institute for Health and Clinical Excellence. Identification and management of familial hypercholesterolaemia (FH) Full guideline. August, 2008 (Reaffirmed 2014; 2015 update, expected publication 2017).*
16. *National Institute for Health and Care Excellence. CG71-Familial hypercholesterolaemia, Surveillance proposal GE document. June 23, 2015:1-35.*
17. *U.S. Food and Drug Administration. FDA News Release: FDA approves Praluent to treat certain patients with high cholesterol. July 24, 2015.*
18. *U.S. Food and Drug Administration. FDA News Release: FDA approves Repatha to treat certain patients with high cholesterol. August 27, 2015.*